Social Anxiety Disorder (SAD)
Neurology
4
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2025
2026
2027
Bristol Myers SquibbNefazodone
Vanda PharmaceuticalsVQW-765
NewleosNTX-1472
Engrail TherapeuticsENX-102
Clinical Trials (4)
Total enrollment: 571 patients across 4 trials
Nefazodone in the Treatment of Social Phobia
Est. completion: Apr 200024 patients
Phase 4Completed
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
Start: Sep 2025Est. completion: Apr 2027500 patients
Phase 3Recruiting
A Study of NTX-1472 in Social Anxiety Disorder
Start: Dec 2025Est. completion: Jan 2027
Phase 2Recruiting
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
Start: Sep 2025Est. completion: Mar 202647 patients
Phase 2Active Not Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
8h ago
Director of Finance
CoMind
London, UK
8h ago
Electronics Engineering Manager
CoMind
London, UK
8h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 571 patients
4 companies competing in this space